Restore the Sensipar Drug to the PBS List. A Critical Bone Drug for Renal Failure Patients
Restore the Sensipar Drug to the PBS List. A Critical Bone Drug for Renal Failure Patients
The issue
This Petition is being created in support of all Renal Patients in Australia who are dependent on the drug - Sensipar. PBS listing occurred on 1 July 2008. This drug was removed in June 2015 from the PBS Drug List controlled by the Federal Government. The Sensipa drug has been on the PBS list as a critical drug for renal failure (Kidney) patients for approximately 7 years. Sensipar (cinacalcet) decreases levels of parathyroid hormone (PTH), calcium, and phosphorous in the body. Sensipar is used to treat hyperparathyroidism (overactive functioning of the parathyroid glands) in people who are on long-term dialysis for kidney disease.
Removing this critical drug in recent cuts to the PBS Listing and the health budget effects thousands of renal failure patients in Australia, who have a small voice, if not silence about the topic, due to the lack of support and advocacy, and simply a sense of disempowerment in their life support health treatments available in Australia, as a 1st World country.
What does Sensipar do?
This hormone strengthens the bodies ability for bone growth, basically regenerating the skeletal structure of the body. Without this hormone action, the skeletal structure is threatened for weakness and ghastly degradation.
Nephrologists Authorise Doctor's Response
Nephrologists (Renal Specialists) are reacting to the removal of Sensipar from the PBS List, not by advocating the reinstatement of this drug on the listing, but by authorising patients to surgery to remove the para thyroid glands from the body. This is a drastic reaction for patients.
The surgical strategy is a costly one for the Medicare system. It is not the best option for patients long term health and survival in Renal failure.
The pharmaceutical company which produces this drug is branded as AMGEN . Sensipar (cinacalcet) decreases levels of parathyroid hormone (PTH), calcium, and phosphorous in the body.
Sensipar is used to treat hyperparathyroidism (overactive functioning of the parathyroid glands) in people who are on long-term dialysis for kidney disease.
WHY IS IT IMPORTANT TO SUPPORT MY PETITION?
The first reason I have started this petition is because of the lack of alternative effective drugs to support the Para Thyroid function for many sensipar patients.
The second reason is that the cost to buy Sensipar at the commercial rate is exorbitant, at what I believe is approximately equal to the Aranesp drug.
The impact on renal patient budgets is estimated to be $1,000 per prescription. This provides 30 tablets per month.
The cost of untreated para thyroid function will have disastrous effects on each patient. Renal patients must be treated with the best and most effective form of drug.
The irreparable damage to the patient inestimable and the chronic disease treatment is essential to life long health.
The issue
This Petition is being created in support of all Renal Patients in Australia who are dependent on the drug - Sensipar. PBS listing occurred on 1 July 2008. This drug was removed in June 2015 from the PBS Drug List controlled by the Federal Government. The Sensipa drug has been on the PBS list as a critical drug for renal failure (Kidney) patients for approximately 7 years. Sensipar (cinacalcet) decreases levels of parathyroid hormone (PTH), calcium, and phosphorous in the body. Sensipar is used to treat hyperparathyroidism (overactive functioning of the parathyroid glands) in people who are on long-term dialysis for kidney disease.
Removing this critical drug in recent cuts to the PBS Listing and the health budget effects thousands of renal failure patients in Australia, who have a small voice, if not silence about the topic, due to the lack of support and advocacy, and simply a sense of disempowerment in their life support health treatments available in Australia, as a 1st World country.
What does Sensipar do?
This hormone strengthens the bodies ability for bone growth, basically regenerating the skeletal structure of the body. Without this hormone action, the skeletal structure is threatened for weakness and ghastly degradation.
Nephrologists Authorise Doctor's Response
Nephrologists (Renal Specialists) are reacting to the removal of Sensipar from the PBS List, not by advocating the reinstatement of this drug on the listing, but by authorising patients to surgery to remove the para thyroid glands from the body. This is a drastic reaction for patients.
The surgical strategy is a costly one for the Medicare system. It is not the best option for patients long term health and survival in Renal failure.
The pharmaceutical company which produces this drug is branded as AMGEN . Sensipar (cinacalcet) decreases levels of parathyroid hormone (PTH), calcium, and phosphorous in the body.
Sensipar is used to treat hyperparathyroidism (overactive functioning of the parathyroid glands) in people who are on long-term dialysis for kidney disease.
WHY IS IT IMPORTANT TO SUPPORT MY PETITION?
The first reason I have started this petition is because of the lack of alternative effective drugs to support the Para Thyroid function for many sensipar patients.
The second reason is that the cost to buy Sensipar at the commercial rate is exorbitant, at what I believe is approximately equal to the Aranesp drug.
The impact on renal patient budgets is estimated to be $1,000 per prescription. This provides 30 tablets per month.
The cost of untreated para thyroid function will have disastrous effects on each patient. Renal patients must be treated with the best and most effective form of drug.
The irreparable damage to the patient inestimable and the chronic disease treatment is essential to life long health.
Petition Closed
Share this petition
The Decision Makers
Petition created on 7 June 2015